Exclusion criteria
liver failure, malignancy, tremor, psychiatric illness, Current infection, hypersensitivity, substance abuse, HIV or active Hep B/C infectionTTV load, HIV or active Hep B/C infectionDonor
LIVER FAILURE, REMISSION, ADENOMA OF THE COLON, HYPERSENSITIVITY, CARDIAC DECOMPENSATION

High-risk HLA-incompatible transplantation (as defined by the local centre; e.g. pre-formed DSA and/or crossmatch conversion).High-risk ABO-incompatible transplantation (as defined by the local centre).Combined transplantationHistory of HIV or active Hep B/C infectionDonor with a history of HIV or active Hep B/C infectionTTV load always below 4.6 log10 c/mL during the screening phaseNo stable TAC trough levels achieved during the screening phase (as defined by the local centre).Hypersensitivity to TAC or other macrolides and hypersensitivity to any excipientsCyclosporine-, mTor inhibitor- or co-stimulation blocker-based immunosuppressionNo standard immunosuppression (according to the local centre definition)Treatment with T-cell-depleting drugs within 2 months before the randomisation (e.g. anti-thymocyte globulin. This intervention has been shown to reduce the TTV replication pool and thus produces false low values [Current infection or allograft rejection as defined by the primary endpointBiopsy-proven ABMR or BKV PCR ≥10Unstable graft function: estimated glomerular filtration rate (eGFR) <25 mL/min/1.73m2 (this limit might be ignored if creatinine clearance is >25 mL/min/1.73mAdvanced liver failure (Child–Pugh score C)History of malignancy other than squamous cell carcinoma or basal cell carcinoma of the skin or carcinoma in situ or adenoma of the colon within the last 5 years unless in complete remission for at least 3 yearsLeukopenia <2000/mmUnstable angina, cardiac decompensation with the necessity for inpatient treatmentSevere tremor (as defined by the local centre) due to TACInability to complete study visits at the trial centreAny state that excludes adherence to the trial protocol, such as serious medical or psychiatric illness, language barrier, alcohol or illicit substance abuse or non-adherenceAddictions or other illnesses that do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequencesSimultaneous participation in another interventional clinical trialPregnant or breastfeeding womenWomen of childbearing potential, except women who meet one of the following criteria:Post-menopausal (12 months’ natural amenorrhoea)Postoperative (6 weeks after bilateral ovariectomy with or without hysterectomy, bilateral salpingectomy)Regular and correct use of a contraceptive method with a Pearl Index <1% per yearSexual abstinenceVasectomy of the partner